CEACAM6 and viral infectious disease: For this experiment, a monolayer of NIH3T3-CD66c cells when treated with mAb anti-CD66c at increasing concentrations of 1.0 μg/mL, 1.5 μg/mL, 2.0 μg/mL and 8.0 μg/mL, preceding virus infection.